Trial | NCT04441658  Report issue

Official Title

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    30
This study is a 24-week single-center, randomized, double-blind, placebo-controlled trial. The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion therapy.
This study is a 24-week single-center, randomized, double-blind, placebo-controlled trial. The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment（including insulin） were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion therapy.
Study Started
Apr 10
2020
Primary Completion
Jul 31
2022
Anticipated
Study Completion
Dec 31
2022
Anticipated
Last Update
Jun 22
2020

Biological Umbilical Cord Mesenchymal Stem Cells

human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group

Biological saline

saline containing human albumin will be infused to the control group

experimental group Experimental

The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75*10^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.

control group Placebo Comparator

The control group will be given the same dose of saline containing human albumin.

Criteria 

Inclusion Criteria:

Type 2 diabetes；
The course of diabetes is 5-15 years;
20kg/m2≤body mass index (BMI)≤30 kg /m2；
7.5% ≤HbA1c≤10%；
Insulin dose and other oral antidiabetic drugs doses should be stable over the 3 months prior to randomization.

Exclusion Criteria:

Heavy allergic constitution or an allergy to any component used in cell culture.
Being treated with drug (Glucocorticoids，Tricyclic Antidepressive Agents,etc.) affect the metabolism of glucose in the past 1 month;
other causes of diabetes;
All kinds of acute complications such as diabetic ketoacidosis and non-ketohyperosmotic syndrome were screened in the past 6 months;
Having evidence of ongoing or frequent/severe hypoglycemia in the past 6 months;
Severe cardiovascular and cerebral events：occurrence of heart failure NYHA Classification III or IV, myocardial infarction, cerebral infarction, cerebral hemorrhage within 6 months before the observation period;
Patients with abnormal liver and kidney function: AST and ALT exceeding 2.5 times of the normal upper limit, and serum creatinine exceeding 1.5 mg/dl for men, exceeding 1.4 mg/dl for women;
Positive results of HbsAg、Anti-HCV、HIV or syphilis;
Patients suffering from other serious systemic diseases (such as malignancy, central nervous system,cardiovascular system, blood system, digestive system,endocrine system,respiratory system, genitourinary system, immune system and);
Ongoing pregnancy or absence of effective contraception in women with childbearing potential;
Patients who had received other stem cell therapy before screening.
No Results Posted